For research use only. Not for therapeutic Use.
Dabrafenib mesylate, also known as GSK 2118436B, is a potent and orally active B-raf (BRAF) inhibitor with in vitro IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2 and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higher concentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth. Dabrafenib inhibits BRAF V600 mutation-positive melanoma cell growth in vitro and in vivo.
| Catalog Number | I006368 |
| CAS Number | 1195768-06-9 (mesylate) |
| Synonyms | Dabrafenib mesylate; GSK 2118436B; GSK2118436B; GSK-2118436B; GSK2118436 Methane sulfonate salt; Brand name: Taflinar.;N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate |
| Molecular Formula | C24H24F3N5O5S3 |
| Purity | ≥95% |
| Target | B-raf (BRAF) inhibitor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic acid |
| InChI | InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4) |
| InChIKey | YKGMKSIHIVVYKY-UHFFFAOYSA-N |
| SMILES | CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O |
| Reference | 1:J Am Pharm Assoc (2003). 2013 Sep-Oct;53(5):550-8. doi: 10.1331/JAPhA.2013.13533. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.Hussar DA,Kaminski JL, PMID: 24030134 DOI: 10.1331/JAPhA.2013.13533 |
